Praxis Precision Medicines Inc (NASDAQ:PRAX) — Market Cap & Net Worth
Market Cap & Net Worth: Praxis Precision Medicines Inc (PRAX)
Praxis Precision Medicines Inc (NASDAQ:PRAX) has a market capitalization of $7.08 Billion ($7.08 Billion) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2819 globally and #1006 in its home market, demonstrating a -4.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Praxis Precision Medicines Inc's stock price $307.83 by its total outstanding shares 27878774 (27.88 Million). Review PRAX total liabilities to assess the company's total debt and financial obligations.
Praxis Precision Medicines Inc Market Cap History: 2020 to 2026
Praxis Precision Medicines Inc's market capitalization history from 2020 to 2026. Data shows change from $23.01 Billion to $8.58 Billion (-5.11% CAGR).
Index Memberships
Praxis Precision Medicines Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.29% | #64 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.02% | #319 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.41% | #42 of 263 |
Weight: Praxis Precision Medicines Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Praxis Precision Medicines Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Praxis Precision Medicines Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
250.85x
Praxis Precision Medicines Inc's market cap is 250.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $995.27 Million | $1.46 Million | -$213.07 Million | 679.83x | N/A |
| 2023 | $621.14 Million | $2.45 Million | -$123.28 Million | 253.84x | N/A |
| 2024 | $2.15 Billion | $8.55 Million | -$182.82 Million | 250.85x | N/A |
Competitor Companies of PRAX by Market Capitalization
Companies near Praxis Precision Medicines Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Praxis Precision Medicines Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Praxis Precision Medicines Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Praxis Precision Medicines Inc's market cap moved from $23.01 Billion to $ 8.58 Billion, with a yearly change of -5.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.58 Billion | +4.44% |
| 2025 | $8.22 Billion | +282.98% |
| 2024 | $2.15 Billion | +245.42% |
| 2023 | $621.14 Million | -37.59% |
| 2022 | $995.27 Million | -87.92% |
| 2021 | $8.24 Billion | -64.19% |
| 2020 | $23.01 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Praxis Precision Medicines Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.08 Billion USD |
| MoneyControl | $7.08 Billion USD |
| MarketWatch | $7.08 Billion USD |
| marketcap.company | $7.08 Billion USD |
| Reuters | $7.08 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Soli… Read more